SkyView Investment Advisors’s LakeShore Biopharma Warrants LSBPW Stock Holding History

SkyView Investment Advisors’s Portfolio LSBPW Stock Details LSBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	12,210	–	–	﹤0.01%	333
2025 Q4	$0	Hold	12,210	–	–	﹤0.01%	348
2025 Q3	$0	Hold	12,210	–	–	﹤0.01%	344
2025 Q2	$0	Hold	12,210	–	–	﹤0.01%	341
2025 Q1	$1K	Hold	12,210	–	–	﹤0.01%	313
2024 Q4	$1K	Hold	12,210	–	–	﹤0.01%	283
2024 Q3	$1K	Hold	12,210	–	–	﹤0.01%	297
2024 Q2	$1K	Hold	12,210	–	–	﹤0.01%	344
2024 Q1	$1K	Hold	12,210	–	–	﹤0.01%	327
2023 Q4	$0	Hold	12,210	–	–	﹤0.01%	507
2023 Q3	$1K	Hold	12,210	–	–	﹤0.01%	585
2023 Q2	$1K	Hold	12,210	–	–	﹤0.01%	748
2023 Q1	$2K	Buy	+12,210	New	+$1.85K	﹤0.01%	577

Other funds holding LSBPW

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

SkyView Investment Advisors's LSBPW Position: Q1 2026 in Review

SkyView Investment Advisors held its LakeShore Biopharma Warrants (LSBPW) position steady in Q1 2026 at 12,210 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #333.

SkyView Investment Advisors first reported a position in LSBPW in Q1 2023 and has held it in 13 quarters since. The position peaked at $2K in Q1 2023. 2 funds tracked by Wall St. Rank hold LSBPW as of Q1 2026.

SkyView Investment Advisors held 12,210 shares of LakeShore Biopharma Warrants worth $0 as of Q1 2026.
SkyView Investment Advisors left its LakeShore Biopharma Warrants share count unchanged in Q1 2026.
LakeShore Biopharma Warrants made up ﹤0.01% of SkyView Investment Advisors's portfolio in Q1 2026, its #333 holding.
SkyView Investment Advisors first reported a position in LakeShore Biopharma Warrants in Q1 2023 and has held it in 13 quarters since.
SkyView Investment Advisors's LakeShore Biopharma Warrants position peaked at $2K in Q1 2023.
2 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q1 2026.

Based on SkyView Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.